Kaneka Corporation
Financial Results Briefing for the Fiscal Year Ending March 2026
For the fiscal year ending March 2026, sales were 811.6 billion yen (+0.5% YoY), operating income was 32.9 billion yen (▼17.9%), and net income was 31.0 billion yen (+22.4%). While sales showed slight growth, net income increased significantly, highlighting the effects of cost reduction and business restructuring. The substantial increase in net income is attributed to foreign exchange fluctuations and strict cost management. Moving forward, the company aims to accelerate new business and overseas expansion to strengthen its earnings foundation.
Key Figures
- Sales: 811.6 billion yen (YoY+0.5%)
- Operating Income: 32.9 billion yen (▼17.9%)
- Net Income: 31.0 billion yen (＋22.4%)
AI要約
Performance Overview
Kaneka Corporation announced its consolidated financial results for the fiscal year ending March 2026, reporting sales of 811.6 billion yen (up 0.5% YoY), operating income of 32.9 billion yen (down 17.9%), and net income of 31.0 billion yen (up 22.4%). Despite slight growth in sales, net income saw a substantial increase, reflecting effects of cost reductions and business restructuring. The notable rise in net income is attributed to foreign exchange movements and stringent cost controls. The company plans to enhance its revenue base by accelerating new businesses and expanding overseas markets.
Future Outlook and Investor Implications
The company's future strategy includes expanding high-value-added businesses such as pharmaceuticals and functional materials, as well as actively pursuing overseas market growth. For the fiscal year ending March 2027, earnings are forecasted to be 820.0 billion yen (up 1.0%), operating income of 36.0 billion yen (up 9.4%), and net income of 31.5 billion yen (up 1.7%). These forecasts indicate steady growth, providing investors with confidence in stable revenue generation and ongoing long-term shareholder returns.
Kaneka Corporation
Company overview · Stock price · Financial data · All IR
